Goldman Sachs Says These ASX 200 Stocks Are Strong Buys
ResMed Inc Reports Changes in CDIs and Securities for April 2025
ResMed Inc To Go Ex-Dividend On May 7th, 2025 With 0.0816 AUD Dividend Per Share
UBS Reaffirms Their Buy Rating on Resmed Inc CHESS Depositary Interests on a Ratio of 10 CDIs per Ord.sh (RMD)
Top Brokers Name 3 ASX Shares to Buy Next Week 4 May 2025
ResMed Acquires US-Based Diagnostic Testing Services Provider for Undisclosed Sum
ResMed: The Acquisition Is Not Material to Resmed's Fincl Results >RMD
Resmed Acquires VirtuOx >RMD
Press Release: Resmed Acquires VirtuOx
Express News | Resmed Inc - Financial Terms of Resmed-Virtuox Acquisition Not Disclosed
Resmed Inc (RMD): Jim Cramer Says "Remarkable Stock" — Did GLP-1 Drugs Just Hand It a Lifeline?
How to Turn $100 a Week Into $500,000 With ASX Shares
This ASX Medical Device Company Has a Trump Tariff Exemption
ResMed Target Price Raised 5.1% to A$49.30/Share by Goldman Sachs>RMD.AU
Leading Brokers Name 3 ASX Shares to Buy Today 28 April 2025
What Does Macquarie Think ResMed Shares Are Worth?
ResMed's Tariff Exemption Should Support Multiples -- Market Talk
Morgans Sticks to Their Buy Rating for Resmed Inc CHESS Depositary Interests on a Ratio of 10 CDIs per Ord.sh (RMD)
ResMed Price Target Cut 1.6% to A$48.00/Share by Macquarie
ResMed Inc. Files Quarterly Report, Reinforces Market Position